Das French National Cancer Institute und XBiotech kooperieren bei einer innovativen, adaptiven, multizentrischen klinischen Studie der Phase II/III zum neuen Arzneimittel von XBiotech gegen das kolorektale Karzinom

NEXT STORY
World-Renowned Cancer Oncologist, Health Consultant and Entrepreneur Dr. Nelson Teich Added to 4D Path’s Distinguished Advisory Board
PREV STORY
The global immunoassay market is projected to reach USD 39.0 billion by 2026 from USD 28.4 billion in 2021, at a CAGR of 6.6%
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Avant Diagnostics Simultaneously Completes Acquisitions of Amarantus Diagnostics and Theranostics Health

Operations of Amarantus Diagnostics and Theranostics Health have consolidated into Avant Diagnostics (OTCQB:AVDX)Diagnostics pipeline ...

author_avatar
NASDAQ Market News

Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease

author_avatar
NASDAQ Market News

Progenics’ Artificial Intelligence Technology for Automated Analysis of PSMA Targeted Prostate Cancer Images to be Featured at the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology ...

author_avatar
NASDAQ Market News